Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 01/30/25
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo MonotherapyBusiness Wire • 01/25/25
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key FactsZacks Investment Research • 01/17/25
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drugCNBC • 01/15/25
Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/13/25
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid TumorsGlobeNewsWire • 01/13/25
Look Out, Interest Rate Cuts Could Be Over: Buy These High-Yield Passive Income Stars Now24/7 Wall Street • 01/10/25
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 01/09/25
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the marketCNBC • 01/08/25
The Magnificent 7 Blue-Chip Dividend Stocks to Buy in 2025 and Hold Forever24/7 Wall Street • 01/06/25
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 01/04/25
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare ConferenceBusiness Wire • 01/03/25
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' ApprovalSeeking Alpha • 12/30/24
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2Business Wire • 12/27/24